| 1 |
factor VIII
(2898 times)
|
Hematology
(1623 times)
|
vWF (654 times)
HA (245 times)
VWD (226 times)
|
1976 Factor VIII synthesis: hepatic and renal allografts in swine with von Willebrand's disease.
|
| 2 |
factor VIII activity
(71 times)
|
Hematology
(42 times)
|
vWF (28 times)
VWD (14 times)
APTT (11 times)
|
1977 Inherited platelet abnormalities associated with low factor VIII activity in the same family.
|
| 3 |
factor VIII coagulant activity
(67 times)
|
Hematology
(47 times)
|
vWF (42 times)
VWD (19 times)
RIPA (4 times)
|
1981 Newborn factor VIII complex: elevated activities in term infants and alterations in electrophoretic mobility related to illness and activated coagulation.
|
| 4 |
anti-factor VIII
(60 times)
|
Hematology
(34 times)
|
vWF (9 times)
HA (3 times)
ITI (3 times)
|
1988 Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.
|
| 5 |
FVIII activity
(42 times)
|
Hematology
(30 times)
|
vWF (12 times)
APTT (7 times)
HA (7 times)
|
2002 A Tyr346-->Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy.
|
| 6 |
FVIII coagulant activity
(24 times)
|
Hematology
(19 times)
|
vWF (18 times)
VWD (4 times)
FIX (2 times)
|
1987 The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
|
| 7 |
factor VIII coagulant
(18 times)
|
Hematology
(7 times)
|
vWF (17 times)
VWD (10 times)
APTT (2 times)
|
1979 Acquired von Willebrand disease associated with an inhibitor to factor VIII antigen and gastrointestinal telangiectasia.
|
| 8 |
factor VIII-related antigen
(17 times)
|
Pathology
(8 times)
|
EMA (2 times)
LCA (2 times)
OS (2 times)
|
1981 Newborn factor VIII complex: elevated activities in term infants and alterations in electrophoretic mobility related to illness and activated coagulation.
|
| 9 |
factor VIII antigen
(12 times)
|
Hematology
(7 times)
|
AvWF (1 time)
BTCs (1 time)
CVD (1 time)
|
1985 Distribution of factor VIII mRNA and antigen in human liver and other tissues.
|
| 10 |
FVIII antigen
(12 times)
|
Hematology
(10 times)
|
VWF (10 times)
ABO (1 time)
APC (1 time)
|
1988 Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
|
| 11 |
factor VIII clotting activity
(7 times)
|
Veterinary Medicine
(2 times)
|
APTT (1 time)
BP (1 time)
CBT (1 time)
|
1998 Type III von Willebrand's disease in Dutch kooiker dogs.
|
| 12 |
FVIII clotting activity
(7 times)
|
Hematology
(6 times)
|
vWF (4 times)
pd (2 times)
PK (2 times)
|
1988 Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
|
| 13 |
factor VIII concentrates
(6 times)
|
Hematology
(6 times)
|
AHC (1 time)
AIDS (1 time)
CI (1 time)
|
1986 Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurization.
|
| 14 |
factor VIII protein
(6 times)
|
Hematology
(5 times)
|
BDD (1 time)
FL (1 time)
HA (1 time)
|
2001 Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients.
|
| 15 |
factor VIII coagulant protein
(4 times)
|
Hematology
(2 times)
|
rhFVIIa (1 time)
|
1984 A moderately severe expression of classical hemophilia in a family of german shepherd dogs.
|
| 16 |
factor VIII gene
(4 times)
|
Hematology
(3 times)
|
HA (4 times)
B2M (1 time)
DHPLC (1 time)
|
2003 Analysis of 18 novel mutations in the factor VIII gene.
|
| 17 |
factor VIII levels
(4 times)
|
Hematology
(2 times)
|
VWF (2 times)
APTT CWA (1 time)
CI (1 time)
|
2010 High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
|
| 18 |
factor VIII (FVIII) coagulant activity
(3 times)
|
Hematology
(3 times)
|
vWF (5 times)
VWD (3 times)
CI (1 time)
|
1992 Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
|
| 19 |
VWF-factor VIII
(3 times)
|
Hematology
(3 times)
|
vWF (2 times)
BsAbs (1 time)
FFP (1 time)
|
2002 Molecular genetics of type 2 von Willebrand disease.
|
| 20 |
factor VIII activity in plasma
(2 times)
|
Biomedical Research
(1 time)
|
---
|
2015 Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.
|
| 21 |
FVIII coagulation
(2 times)
|
Hematology
(1 time)
|
AIS (1 time)
AMI (1 time)
BDD (1 time)
|
2002 Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies.
|
| 22 |
FVIII deficiency
(2 times)
|
Hematology
(2 times)
|
APC (1 time)
HA (1 time)
PCR (1 time)
|
2006 Female hemophilia A heterozygous for a de novo frameshift and a novel missense mutation of factor VIII.
|
| 23 |
FVIII inhibitors
(2 times)
|
Hematology
(1 time)
|
AHA (1 time)
HA (1 time)
IT (1 time)
|
2001 Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
|
| 24 |
FVIII:c
(2 times)
|
Cell Biology
(1 time)
|
CSA (1 time)
MSC (1 time)
OSA (1 time)
|
2012 Mesenchymal stem cells contribute to endogenous FVIII:c production.
|
| 25 |
factor activities
(1 time)
|
Hematology
(1 time)
|
---
|
2004 A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
|
| 26 |
factor VIII (FVIII) activity
(1 time)
|
Hematology
(1 time)
|
VWF (2 times)
HA (1 time)
VWD (1 time)
|
2013 Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
|
| 27 |
factor VIII activity assay
(1 time)
|
Hematology
(1 time)
|
---
|
1997 High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction.
|
| 28 |
factor VIII clot
(1 time)
|
Chemistry, Clinical
(1 time)
|
APTT (1 time)
INR (1 time)
MoM (1 time)
|
2018 Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women.
|
| 29 |
Factor VIII clotting assay
(1 time)
|
Hematology
(1 time)
|
---
|
2006 Accuracy of FVIII: C assay by one-stage method can be improved using hemophilic plasma as diluent.
|
| 30 |
factor VIII components
(1 time)
|
Vascular Diseases
(1 time)
|
---
|
1981 Studies on the haemostatic system in peripheral arterial disease. 2. Variations in factor VIII components (FVIII:C ; FVIIIR:Ag ; FVIII:WF) before and after venous occlusion.
|
| 31 |
factor VIII deficiency
(1 time)
|
Hematology
(1 time)
|
vWd (1 time)
|
1985 A study of cell mediated and humoral immunity in haemophilia and related disorders.
|
| 32 |
factor VIII ristocetin cofactor activity
(1 time)
|
Hematology
(1 time)
|
DIC (1 time)
|
1981 Newborn factor VIII complex: elevated activities in term infants and alterations in electrophoretic mobility related to illness and activated coagulation.
|
| 33 |
factor VIII, IX, XI, XII activity
(1 time)
|
Genetics, Medical
(1 time)
|
APTT (1 time)
ELISA (1 time)
FIB (1 time)
|
2018 [Phenotypic and genetic analysis of two pedigrees affected with hereditary coagulation FXII deficiency].
|
| 34 |
Factor VIII-associated antigen
(1 time)
|
Neurosurgery
(1 time)
|
GKS (1 time)
|
2003 Observations of intracranial neoplasms treated with gamma knife radiosurgery.
|
| 35 |
factor VIII:von Willebrand Factor
(1 time)
|
Hematology
(1 time)
|
HT (1 time)
|
2000 [No ELISA detectable alterations in immunogenicity following dry-hear treatment (72 hours at 80 degrees C) of FANHDI].
|
| 36 |
factor-factor VIII
(1 time)
|
Hematology
(1 time)
|
DVT (1 time)
IVC (1 time)
VTE (1 time)
|
2021 Stabilin-2 deficiency increases thrombotic burden and alters the composition of venous thrombi in a mouse model.
|
| 37 |
factors such as VIII
(1 time)
|
Diagnostic Imaging
(1 time)
|
HP (1 time)
RBCs (1 time)
|
2019 Detection of hemophilia by fluorescence spectroscopy: A photodiagnosis approach.
|
| 38 |
factors VIII and IX activities
(1 time)
|
Clinical Laboratory Techniques
(1 time)
|
---
|
2018 Effects of Freeze-Thaw Times on Screening Coagulation Tests and Factors VIII and IX Activities in Citrate-Anticoagulated Plasma at -20C and -80C.
|
| 39 |
factors VIII, IX, XI, XII
(1 time)
|
Chemistry, Clinical
(1 time)
|
APTT (1 time)
LAC (1 time)
LAC-SR (1 time)
|
2009 Age-associated developmental changes in the activated partial thromboplastin time (APTT) and causes of prolonged APTT values in healthy Chinese children.
|
| 40 |
factorVIII-deficient plasma
(1 time)
|
Hematology
(1 time)
|
APC (1 time)
|
2011 Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.
|
| 41 |
fibrinolytic parameters in these patients.Factor VIII clotting activity
(1 time)
|
Physiology
(1 time)
|
BD (1 time)
MiAU (1 time)
MjAU (1 time)
|
2011 Anticoagulant and Fibrinolytic Disorders in Patients with Behcet's Disease and Recurrent Aphthous Ulcer.
|
| 42 |
five with inhibitors were enrolled at baseline
(1 time)
|
Hematology
(1 time)
|
FXa (1 time)
HA (1 time)
min (1 time)
|
2015 Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).
|
| 43 |
Fuji VIII
(1 time)
|
Dentistry
(1 time)
|
FII (1 time)
FIX (1 time)
FT (1 time)
|
2008 Fluoride content and recharge ability of five glassionomer dental materials.
|
| 44 |
FVIII (rFVIII) activity
(1 time)
|
Hematology
(1 time)
|
rFVIII (1 time)
|
2013 Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
|
| 45 |
FVIII activity level
(1 time)
|
Pathology
(1 time)
|
CWA (1 time)
TGT (1 time)
|
2017 [Development of Comprehensive Coagulation Assays Reflecting the Clinical Phenotype].
|
| 46 |
FVIII assay
(1 time)
|
Hematology
(1 time)
|
MHA (1 time)
TG (1 time)
|
2014 Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements.
|
| 47 |
FVIII chromogenic activity
(1 time)
|
Thrombosis
(1 time)
|
vWF (3 times)
PPP (1 time)
VWD (1 time)
|
2020 A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9.
|
| 48 |
FVIII clotting
(1 time)
|
Biochemistry
(1 time)
|
SEC (1 time)
|
1996 Characterization of aggregates of recombinant human factor VIII by size-exclusion chromatography and immunoassay.
|
| 49 |
FVIII clotting assay
(1 time)
|
Hematology
(1 time)
|
HA (1 time)
|
2015 Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency.
|
| 50 |
FVIII coagulant
(1 time)
|
Hematology
(1 time)
|
RANKL (1 time)
vWF (1 time)
|
2019 Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
|
| 51 |
FVIII concentrates was conducted in twenty-six patients
(1 time)
|
|
HA (1 time)
K 1-0 HL (1 time)
PK (1 time)
|
2022 Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients.
|
| 52 |
FVIII deficiency was classified as mild
(1 time)
|
Veterinary Medicine
(1 time)
|
---
|
2014 Clinical outcome after diagnosis of hemophilia A in dogs.
|
| 53 |
FVIII Delta B
(1 time)
|
Cell Biology
(1 time)
|
EGFP (1 time)
HSC (1 time)
PKC (1 time)
|
2002 Generation and characterization of human hematopoietic cell lines expressing factor VIII.
|
| 54 |
FVIII function
(1 time)
|
Dentistry
(1 time)
|
vWF (2 times)
PT (1 time)
VWD (1 time)
|
2015 Maxillary pseudotumor as initial manifestation of von Willebrand disease, type 2: report of a rare case and literature review.
|
| 55 |
FVIII levels
(1 time)
|
Medicine
(1 time)
|
PK (1 time)
|
2019 Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
|
| 56 |
FVIII levels were determined by one-stage clotting
(1 time)
|
Vascular Diseases
(1 time)
|
CAT (1 time)
TG (1 time)
TGT (1 time)
|
2011 Persistent high factor VIII activity leading to increased thrombin generation - a prospective cohort study.
|
| 57 |
FVIII one-stage clotting value
(1 time)
|
Hematology
(1 time)
|
CAT (1 time)
ETP (1 time)
|
2010 Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
|
| 58 |
FVIII protein content
(1 time)
|
Hematology
(1 time)
|
ELISA (1 time)
pd (1 time)
vWF (1 time)
|
2004 Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
|
| 59 |
FVIII-Ab
(1 time)
|
Hematology
(1 time)
|
HM (1 time)
VWD (1 time)
|
1997 Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.
|
| 60 |
FVIII-LFB, commercialized as Facteur VIII-LFB
(1 time)
|
Hematology
(1 time)
|
vWF (1 time)
|
2007 A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
|
| 61 |
FVIII-ristocetin co-factor activity
(1 time)
|
Veterinary Medicine
(1 time)
|
VWD (1 time)
|
1987 The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
|
| 62 |
FVIII-vWF; one of these two completely inhibited the procoagulant activity
(1 time)
|
Hematology
(1 time)
|
FVIII-vWF (1 time)
|
1984 Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium.
|
| 63 |
FVIII/W ratio
(1 time)
|
Hematology
(1 time)
|
AHA (1 time)
APTT (1 time)
vWF (1 time)
|
2019 The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.
|
| 64 |
FVIII: C were increased markedly in the supernatant of HUVEC
(1 time)
|
Hematology
(1 time)
|
BDDhF VIII cDNA (1 time)
HUVEC (1 time)
|
2007 [Effect of L-arginine on human coagulant factor VIII gene expression].
|
| 65 |
FVIII:C between OSA
(1 time)
|
Hematology
(1 time)
|
CSA (1 time)
HA (1 time)
OSA (1 time)
|
2020 Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.
|
| 66 |
FVIII:C level was assessed using one-stage
(1 time)
|
Hematology
(1 time)
|
CSA (1 time)
OSA (1 time)
|
2020 Discrepancy between the results of one-stage and chromogenic factor VIII: C assays in patients with mild/moderate hemophilia A.
|
| 67 |
FVIII:C of the mutations was determined using two one-stage assays
(1 time)
|
Hematology
(1 time)
|
HA (1 time)
TGT (1 time)
|
2019 In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.
|
| 68 |
FVIII:C results, whereby the one-stage clotting assay
(1 time)
|
Hematology
(1 time)
|
---
|
2013 Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays.
|
| 69 |
FVIII:C to VWF:Ag ratio
(1 time)
|
|
AUC (1 time)
|
2022 Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers.
|
| 70 |
levels-factor VIII
(1 time)
|
Pediatrics
(1 time)
|
vWF (1 time)
|
2019 ABO blood group and procoagulant factors: the hypercoagulation hypothesis ABO and Procoagulant Factors.
|
A Search Service for Abbreviation / Long Form